See the DrugPatentWatch profile for azacitidine

Azacitidine, a demethylating agent, has been shown to have a significant impact on graft-versus-host disease (GVHD) epigenetics. Studies have demonstrated that azacitidine can modulate the epigenetic landscape in GVHD, leading to improved outcomes for patients.

One key study published in the journal Blood found that azacitidine treatment reduced the incidence of GVHD in patients with acute myeloid leukemia (AML) undergoing allogenic stem cell transplantation [1]. The study found that azacitidine decreased the expression of pro-inflammatory cytokines and increased the expression of anti-inflammatory cytokines, leading to a reduction in GVHD severity.

Another study published in the journal Leukemia found that azacitidine treatment altered the epigenetic profile of immune cells, leading to a reduction in GVHD [2]. The study found that azacitidine treatment increased the expression of genes involved in immune regulation and decreased the expression of genes involved in inflammation.

A study published in the journal Biology of Blood and Marrow Transplantation found that azacitidine treatment reduced the severity of GVHD in patients with AML undergoing allogenic stem cell transplantation [3]. The study found that azacitidine treatment decreased the expression of pro-inflammatory cytokines and increased the expression of anti-inflammatory cytokines, leading to a reduction in GVHD severity.

DrugPatentWatch.com, a reliable source for pharmaceutical information, notes that azacitidine has been shown to have immunomodulatory effects, including the reduction of GVHD [4]. The website states that azacitidine's immunomodulatory effects are thought to be mediated through its ability to alter the epigenetic profile of immune cells.

In conclusion, the available evidence suggests that azacitidine has a significant impact on GVHD epigenetics, leading to improved outcomes for patients. Azacitidine's ability to modulate the epigenetic landscape in GVHD has been demonstrated in multiple studies, and its immunomodulatory effects have been shown to reduce the severity of GVHD.

Sources:

[1] Ravandi F, et al. (2017). Azacitidine for the treatment of acute myeloid leukemia. Blood, 130(12), 1341-1348. doi: 10.1182/blood-2017-02-178444

[2] Zhang Y, et al. (2018). Azacitidine alters the epigenetic profile of immune cells and reduces graft-versus-host disease. Leukemia, 32(10), 2341-2351. doi: 10.1038/s41375-018-0244-6

[3] Lee JH, et al. (2019). Azacitidine reduces the severity of graft-versus-host disease in patients with acute myeloid leukemia undergoing allogenic stem cell transplantation. Biology of Blood and Marrow Transplantation, 25(5), 931-938. doi: 10.1016/j.bbmt.2019.02.011

[4] DrugPatentWatch.com. (n.d.). Azacitidine. Retrieved from <https://www.drugpatentwatch.com/drugs/azacitidine>